Vernakalant hydrochlorideProduct ingredient for Vernakalant

Name
Vernakalant hydrochloride
Drug Entry
Vernakalant

Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA.

Accession Number
DBSALT002376
Structure
Synonyms
Vernakalant HCl
External IDs
RSD-1235 / RSD1235